UCHL1

(redirected from Uch-L1)

UCHL1

A gene on chromosome 4p14 that encodes a ubiquitin-protein hydrolase, involved both in processing of ubiquitin precursors and ubiquitinated proteins, which recognises and hydrolyses a peptide bond at the C-terminal glycine of ubiquitin. UCHL1 also binds free monoubiquitin and may prevent its degradation in lysosomes.
References in periodicals archive ?
According to the company, the Brain Trauma Indicator works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury.
For instance, the assays for GFAP and UCH-L1, with an achievement of sub-pg/mL, were both developed in a dedicated research lab created for the development and testing of assays critical in the evaluation of disease biomarkers.
In the creation of assays GFAP and UCH-L1 specifically, the scientists were able to fully characterize and validate the assays for performance, including lower limits of quantitation (LOQ), linear range of calibration, spike recovery, and dilutional linearity.
The development of highly sensitive immunoassays for GFAP, UCH-L1, tau, NfL and A[beta]42 have all been critical in advancing our understanding of the effects of TBIs, bringing us one step closer to a definitive diagnostic test that could one day be used to objectively test for brain injuries, even when symptoms are not overtly present.
Methods: We measured serum levels of TDP-43 and UCH-L1 in 24 children with autism and 24 healthy children.
Results: The mean serum TDP-43 and UCH-L1 levels in children with autism spectrum disorder (ASD) were found to decrease compared to healthy controls (p<0.
Conclusion: Low serum levels of UCH-L1 and TDP-43 may reflect disturbed ubiquitination in autism.
Wada, "The functions of UCH-L1 and its relation to neurodegenerative diseases," Neurochemistry International, vol.
Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1," Proceedings of the National Academy of Sciences of the United States of America, vol.
If further study confirms the value of UCH-L1 as the first clinical biomarker in traumatic brain injury (TBI), physicians will be better able to identify targets for drug therapy and guide the timing of treatment with such agents as tissue plasminogen activator, she explained.
Ventricular CSF was drained from each patient at 6, 12, 24, 48, 72, and 96 hours after TBI and was measured by enzyme-linked immunosorbent assay for UCH-L1 levels.
In this study, EPO in ischemic stroke patients improved neurological outcome and UCH-L1 alone differentiates between placebo and EPO treated patients and correlates with clinical outcome.